Skip to Content Facebook Feature Image

NHS England South East Rolls Out Skin Analytics' AI Skin Cancer Checks in the Largest Deployment of Autonomous Medical AI in NHS History

Business

NHS England South East Rolls Out Skin Analytics' AI Skin Cancer Checks in the Largest Deployment of Autonomous Medical AI in NHS History
Business

Business

NHS England South East Rolls Out Skin Analytics' AI Skin Cancer Checks in the Largest Deployment of Autonomous Medical AI in NHS History

2026-10-08 07:02 Last Updated At:07:20

LONDON--(BUSINESS WIRE)--Oct 7, 2026--

AI will be used to triage skin cancer referrals across the whole of the NHSE South East region, in the largest roll out of autonomous medical AI in NHS history. DERM, developed by Skin Analytics, will go live throughout all 18 NHS South East Trusts from autumn, extending fast, accurate skin cancer detection of a further 9 million people.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007616791/en/

DERM is the first and only AI certified for autonomous use under Class III CE marking, the highest of regulatory scrutiny for a medical device, and is built and regulated in the UK, operating under NHS data governance, clinical safety and security standards throughout.

It has been an integrated part of NHS dermatology pathways for over six years and is already in use in 25 NHS Trusts across NHS England. DERM has assessed over 250,000 patients and found more than 25,000 cancers, validated by histopathology, the diagnostic gold standard, and is independently proven to perform at least as well as a face-to-face dermatologist assessment¹.

Trained to identify patterns and structural features associated with skin cancer with a precision far beyond what the human eye can see, DERM correctly rules out skin cancer 99.5% of the time². Patients with benign lesions can then be safely and autonomously discharged at the triage stage, while anyone flagged as higher risk can be fast tracked to a specialist.

With cases of skin cancer rising, early detection is what most often determines survival rate.

Triaging patients with DERM increases access to early detection, reduces waitlists for specialist care and lowers the downstream cost to the NHS of treating skin cancer at a later, more serious stage.

Modelling for the three-year NHSE South East rollout suggests up to a third of urgent suspected skin cancer referrals could be safely discharged before a patient's first outpatient appointment - releasing an estimated 13,500 consultant hours a year, equivalent to around 27,000 additional appointments across the region. Released at the triage stage, and sustained over three years, capacity at this scale represents significant long term easing of pressure on NHS dermatology pathways. Where there is no wait for triage, treatment can start sooner for patients who need it.

Neil Daly, founder and CEO of Skin Analytics said: “We are delighted to work with NHS England South East on a landmark partnership to improve skin cancer pathways for the entire region. We've helped more than 250,000 patients find more than 25,000 cancers over six years, and this partnership takes a proven technology to a large part of the UK. The NHS is the only health system anywhere to take autonomous AI into cancer pathways at this scale, and that's a real world first that happened here.”

Daghni Rajasingam, Regional Chief Medical Officer for NHS England in the South East, said: “For patients, a suspected cancer referral can be an anxious time. Using AI safely alongside clinical expertise means many people can receive reassurance sooner, while those who need further investigation can be prioritised for specialist care. This rollout will also free up thousands of hours of valuable clinical time, helping teams focus on patients with the most complex needs and creating capacity for thousands more appointments. It is a fantastic example of how the South East is harnessing technology to turn the ambitions of the 10-Year Health Plan into better, faster care - improving access, supporting our workforce and delivering better outcomes for patients.”

Dr Alexandra Kemp is a Consultant Dermatologist and Trust Cancer Clinical Director at Amersham Hospital, part of Buckinghamshire Hospitals NHS Trust, where DERM is already in use. She said: “Across the country referrals for suspected skin cancer are continuing to rise and there are not enough dermatologists to manage these referrals. AI DERM is a clinically proven AI device that has enabled us, through image assessment, to take harmless lesions off the cancer pathway more quickly, allowing the dermatologists in Buckinghamshire to focus time on true skin cancers, and at the same time freeing up more capacity to see other common but sometimes debilitating skin conditions such as eczema, psoriasis and acne.”

The NHSE South East roll out follows Northern Ireland's decision to approve the use of DERM to autonomously assess skin cancer lesions for its population of 1.9 million people.

About Skin Analytics:

Skin Analytics was founded in 2012 by Neil Daly to help more people survive skin cancer.

It began providing teledermatology services in 2015 and has been used by over 40 NHS partners across the UK since 2020. Skin Analytics’ DERM platform has supported the assessment of more than 250,000 NHS patients and detected more than 25,000 cancers.

Clinical studies and post-market surveillance has shown that DERM correctly finds ~98% of skin cancers and rules out skin cancer 99.5% of the time.

DERM is the first and only Class III CE-marked AI as a medical device for skin cancer detection.

DERM can support the autonomous discharge of up to 40% of urgent suspected skin cancer referrals.

https://skin-analytics.com/

¹ https://www.edgehealth.co.uk/wp-content/uploads/2024/08/Evaluating-Pathways-for-AI-Dermatology-in-Skin-Cancer-Detection.pdf

²Skin Analytics post-market surveillance reports

DERM will be used throughout the NHS England South East region from autumn 2026

DERM will be used throughout the NHS England South East region from autumn 2026

WASHINGTON (AP) — A college senior who wants to clean up debris pollution in Earth's orbit and a student who has researched AI use in healthcare are among the 32 Americans named as 2027 Rhodes scholars.

The winners, who were announced on Saturday, have a variety of interests, from bioelectronics to water scarcity to art history. They were chosen from 238 finalists who emerged from more than 1,000 candidates who received formal endorsements from their colleges and universities for the honor.

The students will attend the University of Oxford in England as part of the Rhodes scholar program, which awards more than 100 scholarships worldwide each year for students to pursue two to three years of graduate studies.

Two students are the first-ever Rhodes scholars from their schools — Prairie View A&M University in Texas and The Citadel — The Military College of South Carolina. Harvard University led the way with four 2027 Rhodes scholars, followed by Yale and Princeton with three each.

The winners include:

Evan Garrison, of Webb City, Missouri, a senior at Mississippi State University majoring in aerospace engineering and mathematics. His research includes designing ways to detect objects in space, with an interest in cleaning up orbital debris known as “space junk.” He plans to study mathematical modeling, scientific computing and global governance and diplomacy at Oxford.

Asuka Koda, of New York City, a senior at Yale University majoring in mathematics and philosophy. She has researched AI adoption in healthcare and has been a health and science writer for CNN. She plans to study social science of the internet and international health and tropical medicine at Oxford.

Michael Bueker, from Wellesley, Massachusetts, a senior at Dartmouth College majoring in biomedical engineering. His research has focused on biodegradable, implantable neural stimulators and other ultrathin bioelectronic devices. He also grows giant pumpkins. At Oxford, he intends to study engineering science.

Elizabeth Koenck, of Aurora, Colorado, a senior at Georgetown University majoring in foreign service. Her research has examined water scarcity problems across the Middle East, North Africa and the Colorado River Basin. She plans to pursue degrees in migration studies and water science, policy and management at Oxford.

Sabrina Soriano, of Azusa, California, a senior at Yale University majoring in art history. Her research includes 19th-century French painting, with a focus on the relationship between art, religion and cultural identity. She plans to study history of art and visual culture and visual, material and museum anthropology at Oxford.

Named after British imperialist and benefactor Cecil John Rhodes, the scholarships were established at Oxford in 1903. The program has more than 8,000 alumni, many of whom have pursued careers in government, education, the arts and social justice.

FILE - People walk around Oxford University's campus on Sept. 3, 2017, in Oxford, England. (AP Photo/Caroline Spiezio, File)

FILE - People walk around Oxford University's campus on Sept. 3, 2017, in Oxford, England. (AP Photo/Caroline Spiezio, File)

Recommended Articles